CD40 Ligand antibody (N-Term) (Magnetic Particles)

Catalog No. ABIN1495079

The Rabbit Polyclonal anti-CD40 Ligand antibody has been validated for IP. It is suitable to detect CD40 Ligand in samples from Human, Mouse and Rat.

Quick Overview for CD40 Ligand antibody (N-Term) (Magnetic Particles) (ABIN1495079)

Target: CD40 Ligand (CD40LG)

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CD40 Ligand antibody is conjugated to Magnetic Particles

Application: Immunoprecipitation (IP)

Product Details anti-CD40 Ligand Antibody (Magnetic Particles)

Binding Specificity: N-Term

Specificity: Human, mouse, rat. No cross reactivity with other proteins.

Cross-Reactivity (Details): No cross reactivity with other proteins.

Purification: Immunoaffinity purified

Immunogen: Synthetic peptide corresponding to a sequence at the N-terminal of human CD40L, different from the relative mouse sequence by three amino acids, rat sequence by four amino acids.

Type of Immunogen: Synthetic peptide

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Target Species of Antibody: Human

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: 1 mg/mL magnetic beads in PBS,  pH 7.2, 0.05 mg sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 4°C.

Target Details for CD40 Ligand

Target: CD40 Ligand (CD40LG)

Alternative Name: CD40LG / CD40L / CD154

Background: Name/Gene ID: CD40LG
Family: TNF

Synonyms: CD40LG, CD154, CD154 antigen, CD40-L, CD40 ligand, CD40L, gp39, HIGM1, IGM, IMD3, T-BAM, TNFSF5, CD40 antigen ligand, CD54, HCD40L, T-B cell-activating molecule, T-cell antigen Gp39, TNF-related activation protein

Gene ID: 959

UniProt: P29965

Pathways: NF-kappaB Signaling, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints